Newcells Biotech Limited
  1. Companies
  2. Newcells Biotech Limited
  3. Services
  4. Fibroblast to Myofibroblast Transition ...

Fibroblast to Myofibroblast Transition (FMT) Assay Services

SHARE

In vitro assessment of Fibroblast-to-Myofibroblast transition (FMT). Newcells offers a fast and reliable FMT assay service to evaluate the efficacy of anti-fibrotic compounds using high-content imaging. This customisable, high-throughput assay is well suited to compound screening for small molecules targeting lung fibrosis. Normal repair processes are defective in the fibrotic lung. Repetitive cellular microinjuries and a heightened immune response leads to chronic activation of fibroblasts. Activated fibroblasts differentiate into myofibroblasts, a process known as fibroblast-to-myofibroblast transition (FMT). This persistent myofibroblast phenotype leads to an increased synthesis of extracellular matrix proteins, and their deposition within the lung parenchyma, causing progressive scarring, increased lung stiffness and a loss in lung function. 

Most popular related searches
Fibroblast activation in vivo has been shown to up-regulate the expression of alpha-smooth muscle actin (α-SMA) and ECM associated collagen proteins, two biomarkers used as a measure of fibrosis in vitro. Newcells have developed a robust and validated FMT assay using the well-known fibrotic mediator TGF-β, to allow the quantification of total expression and extracellular deposition of collagen proteins. The FMT assay can be used to assess the ability of small molecules to reduce or increase ECM deposition.

Service outputs
  • Cell number (nuclei staining)
  • Active cell proliferation (EdU incorporation)
  • Deposition of Collagen I and Collagen III by immunocytochemistry
  • Detection of α-SMA
Assays
  • Fibroblast-to-Myofibroblast Transition (FMT) assay
Models
  • Primary human lung fibroblasts
Timeline
  • 2-4 months

Accelerate your lead compound selection by understanding their mode of action in a model of lung fibrosis

  1. Evaluate therapeutic candidates targeting idiopathic pulmonary fibrosis (IPF)
  2. Easily model lung fibrosis in vitro
  3. Accelerate drug discovery